• Print
  • Share
close

Share this on...

Share this site with others using one of these sharing tools.

 

Link to this article

To link to this article, paste this block of HTML code onto your webpage.

Guidelines for sites linking to mayoclinic.org

Wilms' Tumor

Clinical Trials

Cooperative group trials for Wilms tumor have resulted in one of the highest cure rates of any cancer in children or adults. Mayo Clinic is a member of the Children's Oncology Group, a national leading-edge consortium of institutions that developed the Wilms tumor therapies currently in use.

Below is a list of Wilms' Tumor clinical trials from the clinical trials database at Mayo Clinic.

Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor
OBJECTIVES: Primary - Determine the 4-year event-free survival (EFS) of patients with stage IV favorable histology (FH) Wilms tumor with pulmonary metastases only who have complete resolution of pulmonary lesions without whole lung irradiation treated with DD4A chemotherapy comprising vincristine, dactinomycin, and doxorubicin hydrochloride.
Read more

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients Receiving Vincristine for Wilms' Tumor, Rhabdomyosarcoma, Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma
OBJECTIVES: Primary - Compare the effect of glutamic acid vs placebo, in terms of decreasing neurotoxicity as measured by a scored neurologic examination, in young patients undergoing vincristine-containing treatment for Wilms' tumor, rhabdomyosarcoma, acute lymphoblastic leukemia, or non-Hodgkin's lymphoma.
Read more

Study of Kidney Tumors in Young Patients
OBJECTIVES: Primary - Classify patients with renal tumors by histological categorization, surgico-pathological stage, presence of metastases, age at diagnosis, tumor weight, and loss of heterozygosity for chromosomes 1p and 16q, to define eligibility for a series of therapeutic studies.
Read more

  • Print

Find Mayo Clinic on


Terms of Use and Information Applicable to this Site
Copyright ©2001-2012 Mayo Foundation for Medical Education and Research. All Rights Reserved.

.